Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hyperlipidemia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Hyperlipidemia 10
Hyperlipidemia Therapeutics under Development by Companies 12
Hyperlipidemia Therapeutics under Investigation by Universities/Institutes 14
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Hyperlipidemia Therapeutics – Products under Development by Companies 20
Hyperlipidemia Therapeutics – Products under Investigation by Universities/Institutes 21
Companies Involved in Hyperlipidemia Therapeutics Development 22
Takeda Pharmaceutical Company Limited 22
Samyang Corporation 23
Daewoong Pharmaceutical Co., Ltd. 24
Dr. Reddy's Laboratories Limited 25
Aegerion Pharmaceuticals, Inc. 26
Idera Pharmaceuticals, Inc. 27
WhanIn Pharmaceutical Co., Ltd. 28
Hanall Pharmaceutical Co., Ltd. 29
Circ Pharma Limited 30
Ferrer Internacional S.A. 31
Esperion Therapeutics, Inc. 32
CORTRIA Corporation 33
Hyperlipidemia – Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Combination Products 35
Assessment by Route of Administration 36
Assessment by Molecule Type 38
Drug Profiles 40
TAK-085 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
IMO-3100 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IMD5 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CRES Pravastatin - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DRL 17822 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
HL 040 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
TRIA-662 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
ETC-1002 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Atorvastatin for HIV Infections and Hyperlipidemia - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Acetylsalicylic Acid + Simvastatin + Ramipril - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Lomitapide + Zetia - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Lomitapide + Lipitor - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Lomitapide + Fenofibrate - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Alpha-CD - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Raltegravir - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
HL 007 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
HL 007 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Atorvastatin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
PPD 10558 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
HL053 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Drug For Hyperlipidemia - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
NanoActive Atorvastatin - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Pterostilbene - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
JCH2 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
WIB-901H - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Hyperlipidemia Therapeutics – Drug Profile Updates 71
Hyperlipidemia Therapeutics – Discontinued Products 78
Hyperlipidemia Therapeutics - Dormant Products 79
Hyperlipidemia – Product Development Milestones 81
Featured News & Press Releases 81
Mar 19, 2012: Pronova And Takeda Announce Results From Phase III Trial Of TAK-085 At Japanese Circulation Society 81
Jan 25, 2012: FDA Does Not Approve New Indications For ZETIA 82
Sep 29, 2011: Pronova And Takeda Announce Submission Of New Drug Application For TAK-085 In Japan For Treatment Of Hyperlipidemia 82
Jul 25, 2011: Daiichi Sankyo Receives FDA Approval For Welchol sNDA 83
Jun 23, 2011: Idera Pharmaceuticals Presents Mechanism Of Action Data Of IMO-3100 In Preclinical Model Of Arthritis At FOCIS 2011 Annual Meeting 83
Nov 17, 2010: Idera Presents Preclinical Data On Mechanism Of Action Of TLR Antagonist Candidate In Model Of Hyperlipidemia At AHA Meeting 84
Aug 27, 2010: LifeCycle Pharma announces Shionogi Pharma terminates Fenoglide North American commercialization agreement 85
Aug 17, 2010: KineMed’s Study Of Merck’s Ezetimibe To Join Best Of AHA Specialty Conference 2010 85
Jul 28, 2010: Abbott Receives FDA Approval For SIMCOR For New Dosage Strengths 86
Jun 21, 2010: Kowa And Eli Lilly Launch LIVALO In US To Treat Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia 86
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 89
Disclaimer 89
List of Tables
Number of Products Under Development for Hyperlipidemia, H1 2012 10
Products under Development for Hyperlipidemia – Comparative Analysis, H1 2012 11
Number of Products under Development by Companies, H1 2012 13
Number of Products under Investigation by Universities/Institutes, H1 2012 15
Comparative Analysis by Late Stage Development, H1 2012 16
Comparative Analysis by Mid Clinical Stage Development, H1 2012 17
Comparative Analysis by Early Clinical Stage Development, H1 2012 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012 19
Products under Development by Companies, H1 2012 20
Products under Investigation by Universities/Institutes, H1 2012 21
Takeda Pharmaceutical Company Limited, H1 2012 22
Samyang Corporation, H1 2012 23
Daewoong Pharmaceutical Co., Ltd., H1 2012 24
Dr. Reddy's Laboratories Limited, H1 2012 25
Aegerion Pharmaceuticals, Inc., H1 2012 26
Idera Pharmaceuticals, Inc., H1 2012 27
WhanIn Pharmaceutical Co., Ltd., H1 2012 28
Hanall Pharmaceutical Co., Ltd., H1 2012 29
Circ Pharma Limited, H1 2012 30
Ferrer Internacional S.A., H1 2012 31
Esperion Therapeutics, Inc., H1 2012 32
CORTRIA Corporation, H1 2012 33
Assessment by Monotherapy Products, H1 2012 34
Assessment by Combination Products, H1 2012 35
Assessment by Stage and Route of Administration, H1 2012 37
Assessment by Stage and Molecule Type, H1 2012 39
Hyperlipidemia Therapeutics – Drug Profile Updates 71
Hyperlipidemia Therapeutics – Discontinued Products 78
Hyperlipidemia Therapeutics – Dormant Products 79
List of Figures
Number of Products under Development for Hyperlipidemia, H1 2012 10
Products under Development for Hyperlipidemia – Comparative Analysis, H1 2012 11
Products under Development by Companies, H1 2012 12
Products under Investigation by Universities/Institutes, H1 2012 14
Late Stage Products, H1 2012 16
Mid Clinical Stage Products, H1 2012 17
Early Clinical Stage Products, H1 2012 18
Discovery and Pre-Clinical Stage Products, H1 2012 19
Assessment by Monotherapy Products, H1 2012 34
Assessment by Combination Products, H1 2012 35
Assessment by Route of Administration, H1 2012 36
Assessment by Stage and Route of Administration, H1 2012 37
Assessment by Molecule Type, H1 2012 38
Assessment by Stage and Molecule Type, H1 2012 39